ArticleAnalytical and bioanalytical chemistry2026
Plasma LC-HRMS metabolomics in parkinsonian syndromes: comparative evaluation of sample preparation protocols for exploratory metabolic signatures.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Untargeted plasma metabolomics by LC-HRMS is increasingly used to explore candidate biomarkers in neurodegenerative disease, yet the analytical output and downstream biological interpretability remain highly dependent on end-to-end workflow choices. This limits reproducibility and cross-study comparability in parkinsonian syndromes where objective fluid biomarkers for differential diagnosis are still lacking. Here, we implemented a QC-anchored, untargeted LC-HRMS plasma platform to compare sample preparation strategies and to explore disease-associated metabolic patterns across Parkinson's disease (PD), multiple system atrophy-parkinsonian subtype (MSA-P), and progressive supranuclear palsy-parkinsonism (PSP-P) in a prospective single-center cohort (n = 102; 57 PD, 19 MSA-P, 26 PSP-P). Three protein precipitation-based workflows were compared within a harmonized analytical framework: tube precipitation, 96-well precipitation-filtration, and 96-well phospholipid removal. Integrated preparation QCs, system QCs, and blanks supported performance monitoring, while MS
Indexed as
Identifiers
42498788What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.